Lidocaine modulates interleukin-1β and interferon-α2 secretion in LPS with ATP stimulated human peripheral blood mononuclear cells
Abstract
IntroductionLocal anesthetics are canonically used for analgesia and anti-arrhythmic therapy, but increasing evidence indicates additional anti-inflammatory properties, including modulation of purinergic signalling. A recent retrospective observational cohort study indicated that subcutaneous lidocaine–Hydroxypropyl-β-cyclodextrin (HP-β-CD) was associated with sustained improvements in quality of life in patients with neuropathic pain in post-COVID, but the underlying mechanism remains to be established. The aim of this study was to determine whether lidocaine and articaine, alone or in combination with HP-β-CD, modulate in vitro immune cell activation and cytokine secretion in human peripheral blood mononuclear cells (PBMCs).MethodsPBMCs were stimulated using phytohemagglutinin (PHA), lipopolysaccharide (LPS), or LPS combined with adenosine triphosphate (ATP) to engage P2X-associated inflammatory pathways, and compounds were applied both prior to and following stimulation. Cytokine secretion was quantified using a 13-plex immunoassay and cell activation was assessed by flow cytometry.ResultsLidocaine-containing formulations attenuated cytokine secretion most prominently under conditions engaging ATP-dependent signaling, reducing interleukin-1β and interferon-α2, with interleukin-1β suppression being the most consistent effect across stimulation conditions. Articaine showed less consistent immunomodulatory effects than lidocaine, which may reflect its previously reported lack of purinergic receptor inhibition, while HP-β-CD alone did not influence immune activation or cytokine release under any condition.DiscussionTogether, these findings show that lidocaine-containing treatments can modulate cytokine responses in human PBMCs, particularly under LPS with ATP stimulation. These findings identify lidocaine as a modulator of ATP-dependent inflammatory signaling.
Related
- Defining the optimal interferon-stimulated genes panel to reflect serum interferon-α levels in patients with systemic lupus erythematosus.
- Cryopreserved Peripheral Blood Mononuclear Cells Recover Mitochondrial Function Following Overnight Culture Revealed by High-Resolution Respirometry
- Comparative Effects of Acrolein and Glyoxal on Redox Homeostasis, Antioxidant Defense and Membrane Properties in Human Peripheral Blood Mononuclear Cells: An In Vitro Study.
- Expression Analysis of microRNAs in Peripheral Blood Mononuclear Cells in Type 2 Diabetes
- Quantification of Y RNAs in peripheral blood mononuclear cells from patients with ankylosing spondylitis and healthy controls.
BibTeX
@article{oostwouder2026lidocaine,
title = {{Lidocaine modulates interleukin-1β and interferon-α2 secretion in LPS with ATP stimulated human peripheral blood mononuclear cells}},
author = {Cees-Jan Oostwouder and Karin Vos and Mathijs R. Merkus and Casper S. Tolsma and Max B. de Smit and Thomas Telders and David F. A. van Deursen and Femke H. Bouwman and Jos W. R. Twisk and Markus W. Hollmann and Coenraad K. van Kalken},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1900376},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1900376},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Lidocaine modulates interleukin-1β and interferon-α2 secretion in LPS with ATP stimulated human peripheral blood mononuclear cells
AU - Cees-Jan Oostwouder
AU - Karin Vos
AU - Mathijs R. Merkus
AU - Casper S. Tolsma
AU - Max B. de Smit
AU - Thomas Telders
AU - David F. A. van Deursen
AU - Femke H. Bouwman
AU - Jos W. R. Twisk
AU - Markus W. Hollmann
AU - Coenraad K. van Kalken
PY - 2026
DA - 2026/11/03
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1900376
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1900376
AB - IntroductionLocal anesthetics are canonically used for analgesia and anti-arrhythmic therapy, but increasing evidence indicates additional anti-inflammatory properties, including modulation of purinergic signalling. A recent retrospective observational cohort study indicated that subcutaneous lidocaine–Hydroxypropyl-β-cyclodextrin (HP-β-CD) was associated with sustained improvements in quality of life in patients with neuropathic pain in post-COVID, but the underlying mechanism remains to be established. The aim of this study was to determine whether lidocaine and articaine, alone or in combination with HP-β-CD, modulate in vitro immune cell activation and cytokine secretion in human peripheral blood mononuclear cells (PBMCs).MethodsPBMCs were stimulated using phytohemagglutinin (PHA), lipopolysaccharide (LPS), or LPS combined with adenosine triphosphate (ATP) to engage P2X-associated inflammatory pathways, and compounds were applied both prior to and following stimulation. Cytokine secretion was quantified using a 13-plex immunoassay and cell activation was assessed by flow cytometry.ResultsLidocaine-containing formulations attenuated cytokine secretion most prominently under conditions engaging ATP-dependent signaling, reducing interleukin-1β and interferon-α2, with interleukin-1β suppression being the most consistent effect across stimulation conditions. Articaine showed less consistent immunomodulatory effects than lidocaine, which may reflect its previously reported lack of purinergic receptor inhibition, while HP-β-CD alone did not influence immune activation or cytokine release under any condition.DiscussionTogether, these findings show that lidocaine-containing treatments can modulate cytokine responses in human PBMCs, particularly under LPS with ATP stimulation. These findings identify lidocaine as a modulator of ATP-dependent inflammatory signaling.
SN - 1663-9812
ER -